173606-54-7

Basic information

• Product Name: 10-(T-BOC-AMINO)-1-DECANOL
• Synonyms: 10-(T-BOC-AMINO)-1-DECANOL;(10-Hydroxydecyl)carbaMic Acid 1,1-DiMethylethyl Ester;10-tert-ButoxycarbonylaMino-1-decanol;tert-butyl 10-hydroxydecylcarbamate;N-Boc-10-aminodecan-1-ol
• CAS NO: 173606-54-7
• Molecular Formula: C₁₅H₃₁NO₃
• Molecular Weight: 273.41
• Product Categories: Miscellaneous Reagents
• Mol File: 173606-54-7.mol
• Article Data: 9

Chemical Properties

• Melting Point: 48-54°C
• Boiling Point: 387.2°C at 760 mmHg
• Flash Point: 188°C
• Appearance: /
• Density: 0.956g/cm³
• Vapor Pressure: 1.35E-07mmHg at 25°C
• Refractive Index: 1.46
• Storage Temp.: -20°C Freezer
• Solubility: Dichloromethane, Chloroform (Slightly), Ether, Ethyl Acetate, Methanol (Slightly
• CAS DataBase Reference: 10-(T-BOC-AMINO)-1-DECANOL(CAS DataBase Reference)
• NIST Chemistry Reference: 10-(T-BOC-AMINO)-1-DECANOL(173606-54-7)
• EPA Substance Registry System: 10-(T-BOC-AMINO)-1-DECANOL(173606-54-7)

Safety Data

• Hazardous Substances Data: 173606-54-7(Hazardous Substances Data)

Usage

Chemical Properties

White Solid

InChI:InChI=1/C15H31NO3/c1-15(2,3)19-14(18)16-12-10-8-6-4-5-7-9-11-13-17/h17H,4-13H2,1-3H3,(H,16,18)

Upstream product

• 185999-05-7 tert-butyl(dec-9-en-1-yloxy)dimethylsilane 
• 90934-00-2 10-(tert-butyldimethylsilyl)oxydecan-1-ol 
• 1384450-60-5 ((10-azidodecyl)oxy)(tert-butyl)dimethylsilane 
• 13019-22-2 9-Decen-1-ol 
• 161270-70-8 2-(10-hydroxydecyl)-1H-isoindole-1,3(2H)-dione 
• 53463-68-6 1-bromo-10-decanol 
• 23160-46-5 10-amino-1-decanol 
• 24424-99-5 di-tert-butyl dicarbonate 
• 173606-51-4 10-(tert-Butyl-dimethyl-silanyloxy)-decanenitrile 
• 173606-52-5 10-(tert-butyldimethylsilanyloxy)decylamine 
• 149051-24-1 ω-bromononanyl dimethyl-tert-butylsilyl ether 
• 55362-80-6 9-bromononan-1-ol 
• 173606-53-6 tert-butyl (10-((tert-butyldimethylsilyl)oxy)decyl)carbamate 

Downstream Products

• 1009-89-8 azacycloundecan-2-one 
• 887353-29-9 1-[10-(2,3,4,6-O-tetrabenzoyl-β,D-glucopyranos-1-yl)-1-oxodecyl]-4,11-bis-(t-butoxycarbonylmethyl)-8-(10-(t-butoxycarbonylamino)decyl)-1,4,8,11-tetraazacyclotetradecane 
• 24566-82-3 10-bromodecylamine hydrobromide 
• 646-25-3 diaminodecane 
• 173606-50-3 10-(N-tert-butoxycarbonyl)aminodecanoic acid 

Relevant articles and documents

Design, Synthesis, and Biological Evaluation of Lysine Demethylase 5 C Degraders

Lysine demethylase 5 C (KDM5C) controls epigenetic gene expression and is attracting great interest in the field of chemical epigenetics. KDM5C has emerged as a therapeutic target for anti-prostate cancer agents, and recently we identified triazole 1 as an inhibitor of KDM5C. Compound 1 exhibited highly potent KDM5C-inhibitory activity in in vitro enzyme assays, but did not show strong anticancer effects. Therefore, a different approach is needed for the development of anticancer agents targeting KDM5C. Here, we attempted to identify KDM5C degraders by focusing on a protein-knockdown strategy. Compound 3 b, which was designed based on compound 1, degraded KDM5C and inhibited the growth of prostate cancer PC-3 cells more strongly than compound 1. These findings suggest that KDM5C degraders are more effective as anticancer agents than compounds that only inhibit the catalytic activity of KDM5C.

Synthesis and evaluation of tamoxifen derivatives with a long alkyl side chain as selective estrogen receptor down-regulators

Abstract Estrogen receptors (ERs) play a major role in the growth of human breast cancer cells. An antagonist that acts as not only an inhibitor of ligand binding but also an inducer of the down-regulation of ER would be useful for the treatment for ER-po

De-novo designed β-lysine derivatives can both augment and diminish the proliferation rates of E. coli through the action of Elongation Factor P

An investigation into the effect of modified β-lysines on the growth rates of eubacterial cells is reported. It is shown that the effects observed are due to the post translational modification of Elongation Factor P (EFP) with these compounds catalysed b

RADIOPHARMACEUTICAL CONJUGATE

This invention relates new radiopharmaceutical conjugates for use in improved methods of diagnosis and treatment of cancer. The radiopharmaceutical conjugate comprises, in sequence: a metabolite that targets tumour cells, bound to a chelating agent capable of containing a radionuclide.bound to a linker capable of binding with an EPR agent in vitro or in vivo; or a chelating agent capable of containing a radionuclide, bound to a metabolite that targets tumour cells, bound to a linker capable of binding with an EPR agent in vitro or in vivo. The radiopharmaceutical conjugates of the present invention provide active and passive targeted radionuclide delivery systems that can help to improve the biodistribution and pharmacological toxicity of the radiopharmaceuticals used for the diagnosis and therapy of cancer.